Healthcare / BiotechnologyNasdaqCM
$1.37
-0.01 (-0.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-57.1M · quality 73.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$464M
P/E
N/A
•EV/EBITDA
N/A
•ROE
557.7%
↑Gross Margin
N/A
•Debt/Equity
-2.72
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-1295.0%
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.4M · net income $-67.8M · FCF $-57.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | $4.4M | $4.4M | $4.1M | $6.0M | $2.5M | $0.00 | $43000.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $-67.8M | $-67.8M | $-54.1M | $-63.1M | $-86.8M | $-58.4M | $-21.8M | $-20.2M | $-18.2M | $-26.4M | $-16.2M | $-32.0M | $-22.8M |
| EBITDA | $-60.3M | $-60.3M | $-51.4M | $-64.8M | $-88.6M | $-57.8M | — | — | — | — | — | — | — |
| EPS | — | — | -0.20 | -0.26 | -0.38 | -0.30 | -0.31 | -1.46 | -47.40 | -59.40 | -130.80 | -145.20 | — |
| Operating Margin | -1425.7% | -1425.7% | -1350.4% | -1085.7% | -3580.0% | — | -49500.0% | — | — | — | — | — | — |
| Net Margin | -1537.4% | -1537.4% | -1333.0% | -1045.0% | -3488.9% | — | -50748.8% | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||
| Debt/Equity | -2.72 | -2.72 | 1.10 | 0.17 | 0.09 | 0.02 | 0.08 | 0.10 | -0.08 | — | — | — | — |
| Current Ratio | 1.86 | 1.86 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $-57.1M | $-57.1M | $-45.5M | $-72.5M | $-64.5M | $-48.9M | $-15.0M | $-16.9M | $-11.7M | $-23.3M | — | — | — |
| Returns | |||||||||||||
| ROE | 557.7% | 557.7% | -182.4% | -155.5% | -117.3% | -64.0% | -101.3% | -183.7% | 143.4% | -595.6% | -119.5% | -113.6% | -42.0% |
| Valuation | |||||||||||||
| P/B | — | — | 8.19 | 4.03 | 3.77 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| Revenue Growth | 8.8% | 8.8% | -32.8% | 142.6% | — | -100.0% | — | — | — | — | — | — | — |
| EPS Growth | — | — | 23.1% | 31.6% | — | 3.2% | 78.8% | 96.9% | 20.2% | 54.6% | 9.9% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+63.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.20 → n/d
Residual
+63.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.